Information Provided By:
Fly News Breaks for May 3, 2016
BIIB
May 3, 2016 | 10:32 EDT
Piper Jaffray analyst Joshua Schimmer said Biogen's plan to spin off its hemophilia business as an independent, publicly traded company doesn't help transform the company's growth outlook and "is a bit perplexing." Schimmer wonders if there is a "deeper strategic purpose" to the plan, perhaps as part of positioning the company for some sort of transaction. The firm reiterates a Neutral rating on Biogen shares.
News For BIIB From the Last 2 Days
BIIB
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.